Recommendations of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)
Diagnosis and Treatment of Bronchiectasis

https://doi.org/10.1016/S1579-2129(08)60117-2Get rights and content

Bronchiectasis is the end result of several different diseases that share principles of management. The clinical course usually involves chronic bronchial infection and inflammation, which are associated with progression. The cause of bronchiectasis should always be investigated, particularly when it can be treated. We recommend evaluating etiology, symptoms, bronchial colonization and infection, respiratory function, inflammation, structural damage, nutritional status, and quality of life in order to assess severity and to monitor clinical course. Care should be supervised by specialized units, at least when there is a history of chronic bronchial infection, recurrent exacerbations, or a cause that is likely to respond to treatment. Improving symptoms and halting progression are the goals of management, which is based on treatment of the underlying cause and of acute or chronic infections and on the drainage of secretions. Complications that arise must also be treated. Antibiotic prescription is guided by monitoring how well infection is being controlled, and this is indicated by the color of sputum and a reduction in the number of exacerbations. We recommend inhaled antibiotics when bronchial infection is chronic and does not respond to oral antibiotics or when these cause side effects, or when the cause is Pseudomonas species or other bacteria resistant to oral antibiotics. Inhaled administration is also advisable to treat initial colonization by Pseudomonas species.

Las bronquiectasias son el resultado final de enfermedades diferentes que tienen puntos de manejo comunes. Suelen cursar con infección e inflamación bronquiales crónicas que se asocian con progresión. Siempre debe investigarse la etiología, en especial de las tributarias de tratamiento. Para valorar la gravedad y hacer el seguimiento, recomendamos evaluar la etiología, la clínica, la colonización-infección bronquial, la función respiratoria, la inflamación, el daño estructural, el estado nutricional y la calidad de vida. Su atención debería realizarse en unidades especializadas, al menos en casos de infección bronquial crónica, agudizaciones repetidas o etiología susceptible de tratamiento. El tratamiento tiene como objetivo mejorar la clínica y detener la progresión, y se basa en el tratamiento de la etiología, de la infección aguda y crónica, en el drenaje de secreciones y en el tratamiento de las complicaciones. La pauta de administración del antibiótico depende del control de la infección, que se comprueba con el color del esputo y la disminución de las agudizaciones. Recomendamos los antibióticos inhalados en la infección bronquial crónica sin respuesta clínica o con efectos secundarios al antibiótico oral, en la causada por Pseudomonas, en la causada por microorganismos resistentes a los antibióticos orales y en la colonización inicial por Pseudomonas.

References (51)

  • FD McCool et al.

    Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines

    Chest

    (2006)
  • JM Bradley et al.

    Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: an overview of five Cochrane systematic reviews

    Resp Med

    (2006)
  • A O'Donnell et al.

    Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. hDNase study group

    Chest

    (1998)
  • JB Orens et al.

    International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation

    J Heart Lung Transplant

    (2006)
  • PA Flume et al.

    Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health

    Am J Respir Crit Care Med

    (2007)
  • AC Pasteur et al.

    An investigation into causative factors in patients with bronchiectasis

    Am J Respir Crit Care Med

    (2000)
  • D Weycker et al.

    Prevalence and economic burden of bronchiectasis

    Clin Pulm Med

    (2005)
  • M Woodhead et al.

    Guidelines for the management of adult lower respiratory tract infections

    Eur Respir J

    (2005)
  • HJ Schünemann et al.

    An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations

    Am J Respir Crit Care Med

    (2006)
  • EY Kang et al.

    Bronchiectasis: comparison of preoperative thin section CT and pathologic findings in resected specimens

    Radiology

    (1995)
  • J de Gracia et al.

    IgG subclass deficiencies associated with bronchiectasis

    Am J Respir Crit Care Med

    (1996)
  • MJ Rodrigo et al.

    Utility of the antibody response to a conjugated Haemophilus influenzae type b vaccine for diagnosis of primary humoral immunodeficiency

    Am J Respir Crit Care Med

    (2000)
  • J de Gracia et al.

    Genotype-phenotype correlation for pulmonary function in cystic fibrosis

    Thorax

    (2005)
  • PG Noone et al.

    Primary ciliary dyskinesia. Diagnostic and phenotypic features

    Am J Respir Crit Care Med

    (2004)
  • RA Stockley et al.

    Assessment of airway neutrophils by sputum colour: correlation with airways inflammation

    Thorax

    (2001)
  • Cited by (180)

    View all citing articles on Scopus
    View full text